Mode
Text Size
Log in / Sign up

Meta-analysis compares bladder preservation therapy vs cystectomy in elderly muscle-invasive bladder cancer

Meta-analysis compares bladder preservation therapy vs cystectomy in elderly muscle-invasive…
Photo by HI! ESTUDIO / Unsplash
Key Takeaway
Consider that bladder preservation therapy may be an option for elderly patients but is associated with inferior 5-year cancer-specific survival and higher mortality vs cystectomy.

This meta-analysis evaluated outcomes of bladder preservation therapy (BPT) versus radical cystectomy (RC) in elderly patients with muscle-invasive bladder cancer, pooling data from 4888 patients. The analysis found no significant difference in overall survival at 1 year (OR 0.81, 95% CI 0.46-1.41, p=0.45), 5 years (OR 0.83, 95% CI 0.51-1.36, p=0.46), or 10 years (OR 1.09, 95% CI 0.24-4.89, p=0.91). Similarly, 1-year cancer-specific survival showed no significant difference (OR 0.80, 95% CI 0.61-1.04, p=0.10). However, at 5 years, BPT was associated with inferior cancer-specific survival (OR 0.51, 95% CI 0.42-0.63, p<0.00001) and a higher mortality rate (OR 2.06, 95% CI 1.24-3.42, p=0.005). The authors note that BPT appeared more favorable in elderly patients compared with unstratified age groups from other studies, and indirect comparisons within BPT sub-analyses suggested combining transurethral resection with chemoradiotherapy might yield greater benefits. Limitations include high heterogeneity and the retrospective design of included studies, which preclude causal inference. The certainty of evidence is low. Clinicians should interpret these findings cautiously, recognizing that BPT may be a reasonable option for selected elderly patients but with potential trade-offs in long-term cancer-specific survival.

Study Details

Study typeMeta analysis
Sample sizen = 4,888
EvidenceLevel 1
Follow-up120.0 mo
PublishedMay 2026
View Original Abstract ↓
BACKGROUND: The oncological safety of bladder preservation therapy (BPT) versus standard radical cystectomy (RC) in elderly patients with muscle-invasive bladder cancer (MIBC) remains controversial. MATERIALS AND METHODS: Adhering to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 statement and Assessing the Methodological Quality of Systematic Reviews (AMSTAR) guidelines, we conducted a systematic literature review of publications indexed in the PubMed, Embase, Web of Science, and China National Knowledge Infrastructure (CNKI) databases through July 2025. This meta-analysis evaluated the oncological safety of BPT compared with that of RC for the treatment of elderly patients with MIBC. The outcomes were overall survival (OS) rates at 1, 5, and 10 years; cancer-specific survival (CSS) rates at 1 and 5 years; and mortality rates. RESULTS: Our analysis included 8 studies with a total of 4888 patients, comprising 2534 patients undergoing BPT and 2354 undergoing RC. BPT and RC did not differ significantly in 1-year OS (odds ratio [OR]) 0.81; 95% confidence interval [CI] 0.46, 1.41; p = 0.45), 5-year OS (OR 0.83; 95% CI 0.51, 1.36; p = 0.46), 10-year OS (OR 1.09; 95% CI 0.24, 4.89; p = 0.91), and 1-year CSS (OR 0.80; 95% CI 0.61, 1.04; p = 0.10). However, BPT was inferior in terms of 5-year CSS (OR 0.51; 95% CI 0.42, 0.63; p < 0.00001) and exhibited a higher mortality rate (OR 2.06; 95% CI 1.24, 3.42; p = 0.005). CONCLUSIONS: BPT was proven more favorable for elderly patients when contrasted with those of unstratified age groups. Indirect comparisons within BPT sub-analyses suggest that combining transurethral resection of bladder tumors (TURBT) with chemoradiotherapy (CRT) might yield greater benefits than either treatment alone or in dual combination. Due to high heterogeneity and the retrospective design of included studies, the results should be interpreted with caution.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.